Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 18.08.2026 FGBL.LN IE00BYTH6121  781,889.00 USD  81,125,978.90  103.756  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 18.08.2026 FJAN.LN IE000MDKBOB3  150,002.00 USD   4,405,334.32   29.369  ...

ST. LOUIS--(BUSINESS WIRE)--Caleres (NYSE: CAL), a market-leading portfolio of consumer-driven footwear brands, will release its second quarter 2026 financial results before market open on Thursday, September 10, 2026. Following the announcement, company executives will host a conference call at 10 a.m. Eastern Time to discuss results and provide a general business update. Investors, Caleres associates, media, and the public are invited to join the call. Participants in North America can dial (...

PARAMUS, N.J.--(BUSINESS WIRE)--Movado Group, Inc. (NYSE: MOV) invites investors to listen to a live broadcast of the Company's conference call to discuss second quarter fiscal year 2027 earnings results on Wednesday, August 26, 2026, at 9:00 a.m. Eastern Time. A press release detailing the Company’s second quarter fiscal year 2027 results will be issued before the market opens and prior to the call. The conference call will be hosted by Efraim Grinberg, Chairman and Chief Executive Officer, an...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 18.08.2026 GINC LN IE00BD842Y21  858,787.00 USD  58,268,340.35   67.850  ...

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck’s a...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - June 18.08.2026 QJUN.LN IE000HFBJ0U0 4,500,002.00 USD 100,994,986.81   22.443  ...

BOCA RATON, Fla.--(BUSINESS WIRE)--Integrated Dermatology enters the Kentucky market, serving patients in Corbin and Richmond communities....

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - September 18.08.2026 QSEP.LN IE000FQ808R5  350,002.00 USD   8,736,318.07   24.961  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 18.08.2026 GMAY.LN IE000P0FL8E3 1,400,002.00 USD  56,924,358.06   40.660  ...